Single Cell Genome Sequencing Market

Global Single Cell Genome Sequencing Market Size (2023 to 2028)

The global single cell genome sequencing market is expected to grow from USD 5.18 billion by 2028 from USD 2.56 billion in 2023, growing at a CAGR of 15.18% from 2023 to 2028.

Global Single Cell Genome Sequencing Market Share Insights:

• Based on product, the instrument segment held the leading share of the global market in 2022.
• Based on disease type, the cancer segment led the market in 2022.
• Based on region, North America captured the largest share of the global market in 2022.

Impact of COVID-19 on the single cell genome sequencing market:

The COVID-19 pandemic had a favourable impact on the market under investigation. The effect of COVID-19 on single-cell sequencing has been the subject of multiple study investigations that have been published. For instance, research published in September 2020 under the title "Single-cell Landscape of Immunological Responses in Patients with COVID-19" stated that the relationship between the severity of the disease and the host immune response is not fully understood in coronavirus disease (COVID-19), which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. When single-cell sequencing was done on COVID-19 patients, most cell types had a potent interferon- response as well as a general acute inflammatory response. These investigations give an inside look at the use of single-cell sequencing on COVID-19. Like this, a research study published in February 2022 with the title "Integrating Single-Cell Sequencing Data with GWAS Summary Statistics Reveals CD16+ Monocytes and Memory CD8+T Cells Involved in Severe COVID-19" reported that there was a significant genetics-modulated immunological shift between mild and severe infection, including an increased expression of genetics-risk genes and increase in inflammatory cytokines. As a result, these investigations provide light on COVID-19 and boost future market expansion.

MARKET DRIVERS:

The growing cancer incidence worldwide is one of the major factors propelling the growth of the single cell genome sequencing market growth. Cancer is the second serious cause of death in the United States, according to the American Cancer Society. According to cancer statistics, the United States have 1.9 million new cases of cancer in 2022. According to information provided by Globocan 2020, the country recorded 195,449 new cases of cancer in 2020. Genome sequencing is becoming increasingly necessary due to the rising prevalence of cancer, which is driving the need for additional research and experimentation and drives market expansion. 

The growing number of new product launches contributes to the global market growth. For instance, Stilla Technologies introduced "the six-colour Prism," one of the first six-colour digital PCR devices in the world, in 2020. This technology has a wide range of applications in cancer, gene therapy, infectious illness, disease monitoring, and food testing. The CFX Opus Deepwell real-time PCR detection device was introduced by Bio-Rad in 2022. Researchers may create nucleic acid detection assays with the use of Bio-Rad's CFx Opus Deepwell Real-time PCR Detection equipment.

The growing funding and collaboration activities by key market players for higher R&D activities and drug development procedures further promote the growth of the single cell genome sequencing market. For instance, the NIH received almost USD 230 billion to research medications and targets, as reported in the 2020 article "United States Tax Dollars Funded Every New Pharmaceutical in the Last Decade ". Such support for biotechnology advances PCR equipment research and utilisation, which drives the market growth. The collaboration among the major market players and research institutes for the research and development of several new diagnostics and treatment methods with the help of the sequencing method is also increasing the market's growth. For instance, Illumina and Israel-based Danyel Biotech stated that scientists at the Weizmann Institute of Science in Israel are now using Illumina's next-generation sequencing (NGS) technology in 2020. Thus, this factor boosts market growth.

The growing adoption of personalized medicine, rising demand for understanding cellular heterogeneity in disease research, emergence of microfluidics-based platforms for high-throughput single cell sequencing and increasing application of single cell genome sequencing in cancer research for targeted therapy development and rise in funding for genomics research and technological innovations promotes the market growth.

MARKET RESTRAINTS:

Complex data analysis requirements and limited bioinformatics expertise, high costs associated with single cell genome sequencing technologies, variability and limitations in capturing complete cellular genomic information and challenges in isolating and preparing single cells for sequencing majorly hamper the growth of the single cell genome sequencing market. Limited throughput and scalability for high-throughput applications, potential sample contamination during single cell handling and processing, lack of standardized protocols for single cell genome sequencing and technological limitations in detecting structural variations and copy number alterations hinder the market growth.

REPORT COVERAGE: 

This research report on global single cell genome sequencing market has been segmented and sub-segmented based on the following categories.

Single Cell Genome Sequencing Market - By Product:

• Instruments
• Reagents

Based on product, the instruments segment is expected to account of the major share of the global market during the forecast period owing to the growing demand for advanced sequencing platforms that offer high-throughput and single cell resolution and technological advancements in sequencing platforms. The growing research interest in understanding cellular heterogeneity at the genomic level and increasing investments in innovative sequencing technologies that cater to single cell applications further fuel the growth rate of the instruments segment in the global market.

Single Cell Genome Sequencing Market - By Technology:

• NGS
• PCR
• qPCR
• Microarray
• MDA

Based on technology, the NGS segment is expected to dominate the market during the forecast period. The growing usage of NGS in various research applications owing to the high-throughput capabilities of NGS that enable comprehensive analysis of single cell genomes and transcriptomes is one of the major factors driving the growth of NGS segment. The rising demand for high-resolution genomic and transcriptomic data at the single cell level, continuous advancements in NGS technology and the ability to perform multi-omics analysis on single cells fuel the growth rate of the NGS segment.

The PCR segment is anticipated to account for a substantial share of the worldwide market in the coming years. PCR is established and widely used technique for DNA/RNA amplification from limited samples, which is one of the key factors driving the growth of the PCR segment. Compatibility with low input amounts, characteristic of single cell analysis and the customizability for targeted analysis of specific genomic regions or transcripts boosts the growth rate of the PCR segment in the global market.

Single Cell Genome Sequencing Market - By Disease Type:

• Cancer
• Immunology
• Prenatal diagnosis
• Neurobiology
• Microbiology
• Others

Based on disease type, the cancer segment dominated the single cell genome sequencing market in 2022 and is expected to account for a notable share of the worldwide market during the forecast period. The increasing incidence of prostate, colorectal, and breast cancer is fuelling the need for single cell genome sequencing and driving the segmental growth. According to the American Cancer Society, in the U.S., there are anticipated to be 1,918,030 new cancer cases and 609,360 cancer deaths in 2022, with lung cancer being the primary cause of death accounting for around 350 of those fatalities daily.

Single Cell Genome Sequencing Market - By Application:

• CTCs
• Differentiation/ Reprogramming
• Genomic Variation
• Subpopulation Characterization
• Others

Based on application, the genomic variation segment is estimated to account for the major share of the global market during the forecast period owing to the advances in single cell sequencing technologies, growing interest in understanding genetic heterogeneity in diseases and developmental processes and clinical relevance in cancer research and precision medicine applications.

Single Cell Genome Sequencing Market - By End-user:

• Academic & Research Laboratories
• Biotechnology & biopharmaceutical companies
• Clinics
• Others

Based on end-user, the academic and research laboratories segment is anticipated to hold the largest share of the global market during the forecast period. Factors such as the growing emphasis on understanding cellular diversity and its implications, the availability of research funding and grants supporting single cell genomics projects and collaborative efforts among academic institutions to share knowledge and resources drive the growth of the academic and research laboratories segment.

Single Cell Genome Sequencing Market - By Region:

• North America
• Europe
• Asia-Pacific
• Latin America
• The Middle East & Africa

North America had the largest share of the worldwide market in 2022 and the domination of the regional market is expected to continue throughout the forecast period. Factors such as the strong presence of key biotechnology and pharmaceutical companies driving technology adoption, the availability of research funding and collaborations among academic institutions and the high prevalence of chronic diseases and the need for precise genetic insights majorly propel the growth of the North American market. The U.S. is expected to hold the leading share of the North American market in the coming years due to its well-established healthcare infrastructure, advanced research facilities, and significant investments in genomics research.

Europe is anticipated to account for a noteworthy share of the worldwide market during the forecast period. Europe is considered as a major contributor to the global market due to its research-oriented healthcare systems. Advancements in genomics research that drive the adoption of cutting-edge technologies, efforts to establish national genomics initiatives and data sharing platforms and growing focus on rare diseases and population-level genomics studies propel the growth of the European market. The UK and Germany are expected to hold the leading share of the European market in the coming years.

APAC is the most lucrative regional market single cell genome sequencing and is predicted to occupy a considerable share of the worldwide market during the forecast period. Asia-Pacific is also the fastest-growing region in the single cell genome sequencing market. The growing adoption of genomics technologies and personalized medicine approaches, rise in research collaborations between Asian countries and Western institutions and high population diversity offering opportunities for genomics studies drive the growth of the APAC market.

KEY MARKET PLAYERS:

Some of the notable key market players include Oxford Nanopore Technologies plc (U.K.), PacBio (U.S., Novogene Co, Ltd (China), Mission Bio (U.S)., Fluxion Biosciences Inc (U.S.), Thermo Fisher Scientific (U.S.), QIAGEN (Netherlands), Agilent Technologies, Inc. (U.S.), McKesson Corporation (U.S), Allscripts Healthcare, LLC, (U.S, Siemens, (Germany), F. Hoffmann-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (U.S.), BGI (China), B.D. (U.S.), Danaher (U.S.), Bruker (U.S.), 10x Genomics (U.S.), Promega Corporation (U.S.)

RECENT HAPPENINGS IN THE MARKET:

• In Feb 2022, Illumina, the leading maker of gene-sequencing machines announced its acquisition plan in September. Six months later, the Federal Trade Commission filed a complaint to block the deal, saying Illumina would have the gatekeeper power and the financial incentive to throttle Grail’s rivals.
• In June 2018, QIAGEN launched QIAseq 16S/ITS Panels and UCP Multiplex PCR Kit with a new generation of reagents that enables the most accurate microbial community profiling from complex microbiome samples and is used for single-cell sequencing.